Last reviewed · How we verify
NCT04032353
Medical Consortium for Screening Upper Gastrointestinal Cancers With Magnetically Controlled Capsule Gastroscopy
NA trial testing Medical Consortium in Capsule Endoscopy in 10,000 participants. Status unknown.
31 December 2019
Quick facts
| Lead sponsor | Yanqing Li |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 10,000 |
| Start date | 31 December 2018 |
| Primary completion | 31 December 2019 |
| Estimated completion | 1 March 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Medical Consortium
Conditions studied
- Capsule Endoscopy — all drugs for Capsule Endoscopy →
- Cancer of Stomach — all drugs for Cancer of Stomach →
- Cancer of Esophagus — all drugs for Cancer of Esophagus →
- Health Policy — all drugs for Health Policy →
Sponsor
Yanqing Li — full company profile →
Who can join
Adults 18 to 80, any sex, with Capsule Endoscopy or Cancer of Stomach. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of our study was to demonstrate the efficacy and feasibility of the medical consortium for screening upper gastrointestinal cancers with magnetically controlled capsule gastroscopy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04032353
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Capsule Endoscopy
Currently open trials in the same condition.
- NCT07325344 — Active Locomotion of Magnetically Controlled Capsule Endoscopy in the Small Bowel: A Feasibility Study · NA · recruiting
Other Yanqing Li trials
Trials by the same sponsor.
- NCT07179159 — Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication · NA · recruiting
- NCT06936800 — Pinaverium Bromide Preventing Post Extracorporeal Shock Wave Lithotripsy Pancreatitis and Painful (PBPEP) · NA · enrolling by invitation
- NCT05870683 — Comparison of Two Dual Therapies in the First-line Treatment of Helicobacter Pylori Infection （SHARE2301） · NA · unknown
- NCT05458388 — Different Endoscopic Gastric Cancer Risk Assessments · NA · unknown
- NCT05277090 — Bowel Preparation May Lead to a Higher Feasibility of Intestinal Infection · EARLY_PHASE1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04032353 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yanqing Li
- Last refreshed: 25 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04032353.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing